The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2023 | WGS reveals sequential & persistent loss of BCMA and GPRC5D after bispecific antibodies in myeloma
In this video, Leo Rasche, MD, University of Würzburg, Würzburg, Germany, discusses a recent study in which whole-genome sequencing (WGS) data demonstrated a loss of BCMA and GPRC5D in patients with relapsed/refractory (R/R) multiple myeloma treated with bispecific antibodies. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
